Translational Oncology (Jan 2019)

mTORC1 Prevents Epithelial Damage During Inflammation and Inhibits Colitis-Associated Colorectal Cancer Development

  • I.Z. Gutiérrez-Martínez,
  • J.F. Rubio,
  • Z.L. Piedra-Quintero,
  • O. Lopez-Mendez,
  • C. Serrano,
  • E. Reyes-Maldonado,
  • C. Salinas-Lara,
  • A. Betanzos,
  • M. Shibayama,
  • A. Silva-Olivares,
  • A. Candelario-Martinez,
  • M.A. Meraz-Ríos,
  • M. Schnoor,
  • N. Villegas-Sepúlveda,
  • P. Nava

Journal volume & issue
Vol. 12, no. 1
pp. 24 – 35

Abstract

Read online

Epithelial cells lining the intestinal mucosa constitute a selective-semipermeable barrier acting as first line of defense in the organism. The number of those cells remains constant during physiological conditions, but disruption of epithelial cell homeostasis has been observed in several pathologies. During colitis, epithelial cell proliferation decreases and cell death augments. The mechanism responsible for these changes remains unknown. Here, we show that the pro-inflammatory cytokine IFNγ contributes to the inhibition of epithelial cell proliferation in intestinal epithelial cells (IECs) by inducing the activation of mTORC1. Activation of mTORC1 in response to IFNγ was detected in IECs present along the crypt axis and in colonic macrophages. mTORC1 inhibition enhances cell proliferation, increases DNA damage in IEC. In macrophages, mTORC1 inhibition strongly reduces the expression of pro-inflammatory markers. As a consequence, mTORC1 inhibition exacerbated disease activity, increased mucosal damage, enhanced ulceration, augmented cell infiltration, decreased survival and stimulated tumor formation in a model of colorectal cancer CRC associated to colitis. Thus, our findings suggest that mTORC1 signaling downstream of IFNγ prevents epithelial DNA damage and cancer development during colitis.